Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. is progressing with its gene therapy programs, having received positive safety reviews from independent Data Safety and Monitoring Boards (DSMB) to advance its clinical trials, including the Phase 1b/2 MyPEAK-1 trial and the Phase 1b RIDGE-1 trial. The company's commitment to developing therapies for heart disease is underscored by its successful enrollment of patients in critical trial cohorts, indicating strong operational momentum and patient engagement. Furthermore, initial modeling linked Left Ventricular Mass Index (LVMI) with significant predictive risk, highlighting the potential for Tenaya’s therapies to address critical health markers in cardiovascular diseases.

Bears say

Tenaya Therapeutics faces a negative outlook largely due to potential setbacks in its clinical trials, which can result in failed or inconclusive results that could adversely impact the company's future. Furthermore, there is significant concern regarding the company's ability to secure sufficient funding to progress its drug development, which is critical for a preclinical-stage biotechnology firm. Lastly, the risk of dilutive capital raises adds to the uncertainty surrounding its financial stability and growth prospects.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.